Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Mak

Showing results (541-550 of 550) with videos related to

Pageof 55
Sort By:
You have reached the last page of results.This site can display upto 550 results.
Seminars in Thoracic and Cardiovascular Surgery|December 14, 2024
Systematic Review of Sublobar Resection for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung CancerRobert E Merritt, Alessandro Brunelli, Garrett Walsh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2026
Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung CancerIvy S Han, Kyunga Ko, Jennifer Wei Zou, et al.
Cancer Research|May 18, 2022
Pyruvate Kinase M1 Suppresses Development and Progression of Prostate AdenocarcinomaShawn M Davidson, Daniel R Schmidt, Julia E Heyman, et al.
Clinical and Translational Radiation Oncology|December 3, 2025
Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective studyNikhil Yegya-Raman, Kyunga Ko, Ivy S Han, et al.
The Lancet. Digital Health|May 27, 2026
Artificial intelligence analysis of temporalis muscle thickness for monitoring sarcopenia and clinical outcomes in individuals with paediatric brain tumours: a retrospective cohort studyAnna Zapaishchykova, John Zielke, Divyanshu Tak, et al.
Medrxiv : the Preprint Server for Health Sciences|March 23, 2026
An agentic AI system enhances clinical detection of immunotherapy toxicities: a multi-phase validation studyJack Gallifant, Shan Chen, Kee-Young Shin, et al.
The Lancet. Oncology|January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trialJonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Clinical Pharmacology and Therapeutics|November 25, 2015
HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosisC-L Cheung, C-W Sing, C S M Tang, et al.
Nature Medicine|April 12, 2023
Body composition and lung cancer-associated cachexia in TRACERxOthman Al-Sawaf, Jakob Weiss, Marcin Skrzypski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.
Pageof 55

Showing results (541-550 of 550) with videos related to

Sort By:
Pageof 55
You have reached the last page of results.This site can display upto 550 results.
Seminars in Thoracic and Cardiovascular Surgery|December 14, 2024
Systematic Review of Sublobar Resection for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung CancerRobert E Merritt, Alessandro Brunelli, Garrett Walsh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2026
Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung CancerIvy S Han, Kyunga Ko, Jennifer Wei Zou, et al.
Cancer Research|May 18, 2022
Pyruvate Kinase M1 Suppresses Development and Progression of Prostate AdenocarcinomaShawn M Davidson, Daniel R Schmidt, Julia E Heyman, et al.
Clinical and Translational Radiation Oncology|December 3, 2025
Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective studyNikhil Yegya-Raman, Kyunga Ko, Ivy S Han, et al.
The Lancet. Digital Health|May 27, 2026
Artificial intelligence analysis of temporalis muscle thickness for monitoring sarcopenia and clinical outcomes in individuals with paediatric brain tumours: a retrospective cohort studyAnna Zapaishchykova, John Zielke, Divyanshu Tak, et al.
Medrxiv : the Preprint Server for Health Sciences|March 23, 2026
An agentic AI system enhances clinical detection of immunotherapy toxicities: a multi-phase validation studyJack Gallifant, Shan Chen, Kee-Young Shin, et al.
The Lancet. Oncology|January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trialJonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Clinical Pharmacology and Therapeutics|November 25, 2015
HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosisC-L Cheung, C-W Sing, C S M Tang, et al.
Nature Medicine|April 12, 2023
Body composition and lung cancer-associated cachexia in TRACERxOthman Al-Sawaf, Jakob Weiss, Marcin Skrzypski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.
Pageof 55